ADAMTS13 Gene

ADAMTS13 Gene

Overview

<div class="infobox infobox-gene">
<table>
<tr><th colspan="2" style="background:#f0f0f0;">ADAMTS13 Gene</th></tr>
<tr><td><b>Official Symbol</b></td><td>ADAMTS13</td></tr>
<tr><td><b>Full Name</b></td><td>A Disintegrin And Metalloproteinase with Thrombospondin Motifs 13</td></tr>
<tr><td><b>Chromosomal Location</b></td><td>9q34.2</td></tr>
<tr><td><b>NCBI Gene ID</b></td><td>https://www.ncbi.nlm.nih.gov/gene/11067 11067</td></tr>
<tr><td><b>OMIM</b></td><td>https://www.omim.org/entry/607840 607840</td></tr>
<tr><td><b>Ensembl ID</b></td><td>ENSG00000162825</td></tr>
<tr><td><b>UniProt ID</b></td><td>https://www.uniprot.org/uniprot/Q76LX8 Q76LX8</td></tr>
<tr><td><b>Associated Diseases</b></td><td>Thrombotic Thrombocytopenic Purpura (TTP), AD, stroke</td></tr>
</table>
</div>

Function

ADAMTS13 is a zinc-dependent metalloprotease that specifically cleaves von Willebrand factor (VWF) multimers into smaller, less pro-thrombotic units. This cleavage is essential for normal hemostasis, as it prevents the formation of unusually large VWF multimers that can cause platelet aggregation and microvascular thrombosis [1].

The protein consists of multiple domains including a propeptide, a metalloprotease domain, a disintegrin domain, multiple thrombospondin type 1 repeats (TSRs), a cysteine-rich domain, a spacer domain, and two CUB domains. The enzyme is primarily expressed in the liver, particularly by hepatic stellate cells and endothelial cells [2].

ADAMTS13 Gene

Overview

<div class="infobox infobox-gene">
<table>
<tr><th colspan="2" style="background:#f0f0f0;">ADAMTS13 Gene</th></tr>
<tr><td><b>Official Symbol</b></td><td>ADAMTS13</td></tr>
<tr><td><b>Full Name</b></td><td>A Disintegrin And Metalloproteinase with Thrombospondin Motifs 13</td></tr>
<tr><td><b>Chromosomal Location</b></td><td>9q34.2</td></tr>
<tr><td><b>NCBI Gene ID</b></td><td>https://www.ncbi.nlm.nih.gov/gene/11067 11067</td></tr>
<tr><td><b>OMIM</b></td><td>https://www.omim.org/entry/607840 607840</td></tr>
<tr><td><b>Ensembl ID</b></td><td>ENSG00000162825</td></tr>
<tr><td><b>UniProt ID</b></td><td>https://www.uniprot.org/uniprot/Q76LX8 Q76LX8</td></tr>
<tr><td><b>Associated Diseases</b></td><td>Thrombotic Thrombocytopenic Purpura (TTP), AD, stroke</td></tr>
</table>
</div>

Function

ADAMTS13 is a zinc-dependent metalloprotease that specifically cleaves von Willebrand factor (VWF) multimers into smaller, less pro-thrombotic units. This cleavage is essential for normal hemostasis, as it prevents the formation of unusually large VWF multimers that can cause platelet aggregation and microvascular thrombosis [1].

The protein consists of multiple domains including a propeptide, a metalloprotease domain, a disintegrin domain, multiple thrombospondin type 1 repeats (TSRs), a cysteine-rich domain, a spacer domain, and two CUB domains. The enzyme is primarily expressed in the liver, particularly by hepatic stellate cells and endothelial cells [2].

In the central nervous system, ADAMTS13 is expressed by microvascular endothelial cells and [astrocytes](/entities/astrocytes). It plays a protective role in the [blood-brain barrier](/entities/blood-brain-barrier) (BBB) by regulating VWF-mediated platelet adhesion and preventing microthrombus formation in cerebral vasculature [3].

Disease Associations

Alzheimer's Disease

• Increased VWF multimers in AD patients contribute to cerebral microvascular dysfunction
• Impaired clearance of VWF-[Aβ](/proteins/amyloid-beta) complexes leads to accumulation of amyloid in cerebral vessels
• Microvascular inflammation and reduced cerebral blood flow [4]

Stroke

• ADAMTS13 polymorphisms are associated with stroke risk
• Low ADAMTS13 activity predicts poor outcomes after ischemic stroke
• The enzyme provides neuroprotection by preventing thrombotic complications [5]

Thrombotic Microangiopathy

• Congenital or acquired ADAMTS13 deficiency causes TTP
• Neurological symptoms in TTP include stroke, transient ischemic attacks, and cognitive impairment

Expression

ADAMTS13 is expressed in:

• Liver: Primary site of synthesis (hepatocytes and hepatic stellate cells)
• Brain: Cerebral microvascular endothelial cells, astrocytes
• Kidney: Glomerular endothelial cells
• Plasma: Circulating enzyme at concentrations of ~1 μg/mL

• Cerebral [cortex](/brain-regions/cortex) (layer IV)
• [Hippocampus](/brain-regions/hippocampus) (CA1 region)
• Cerebellum (Purkinje cell layer)

Common Variants

| Variant | Effect | Association |
|---------|--------|-------------|
| Q449E | Reduced activity | TTP risk |
| P618A | Mild reduction | Stroke risk |
| R7W | Altered secretion | TTP risk |

Therapeutic Implications

• Recombinant ADAMTS13: Being developed for congenital TTP; potential neuroprotective therapy
• ADAMTS13 agonists: Natural compounds that enhance ADAMTS13 activity may benefit AD
• Gene therapy: AAV-mediated ADAMTS13 expression under investigation

Molecular Mechanisms in Alzheimer's Disease

Von Willebrand Factor and Amyloid-beta Interaction

The relationship between [von Willebrand factor](/proteins/vwf) (VWF) and [amyloid-beta](/proteins/amyloid-beta) (Aβ) represents a critical link between vascular dysfunction and neurodegeneration in AD[@zhang2022]:

VWF-Aβ Complex Formation

ADAMTS13's Protective Role

ADAMTS13 provides neuroprotection through several mechanisms:

Blood-Brain Barrier Dysfunction

ADAMTS13 plays a crucial role in maintaining [blood-brain barrier](/mechanisms/blood-brain-barrier) (BBB) integrity[@chauhan2021]:

BBB Components Affected

• Endothelial cells: ADAMTS13 regulates VWF-mediated endothelial activation
• Tight junctions: VWF dysregulation disrupts tight junction proteins (claudin-5, occludin, ZO-1)
• Astrocyte end-feet: Perivascular astrocyte function is impaired by VWF deposits
• Pericyte coverage: Microvascular pericytes are affected by microthrombi

ADAMTS13 Protection Mechanisms

| Mechanism | Effect on BBB |
|-----------|---------------|
| VWF cleavage | Prevents microthrombus formation |
| Platelet regulation | Reduces platelet-endothelial interaction |
| Inflammation reduction | Decreases cytokine-mediated barrier disruption |
| Matrix preservation | Maintains basement membrane integrity |

Cerebral Microvascular Function

ADAMTS13 deficiency contributes to cerebral microvascular dysfunction in multiple ways:

Microvascular Occlusion

• Large VWF multimers form microthrombi in cerebral capillaries
• These occlusions reduce cerebral blood flow (CBF)
• Chronic hypoperfusion contributes to cognitive decline
• Ischemic events accelerate neurodegeneration

Endothelial Activation

• Elevated VWF indicates endothelial activation/dysfunction
• Pro-inflammatory state in cerebral vasculature
• Increased adhesion molecule expression (VCAM-1, ICAM-1)
• Enhanced leukocyte recruitment to brain parenchyma

Clinical Implications

ADAMTS13 as a Biomarker

Diagnostic Potential

| Marker | Utility | Evidence Level |
|--------|---------|----------------|
| Plasma ADAMTS13 activity | AD diagnosis | Moderate |
| VWF:ADAMTS13 ratio | Disease severity | Emerging |
| CSF ADAMTS13 | BBB integrity | Limited |
| Genetic variants | Risk prediction | Research stage |

Disease Progression Markers

• Early AD: Reduced ADAMTS13 activity may precede clinical symptoms
• Mild cognitive impairment: VWF:ADAMTS13 ratio correlates with conversion to AD
• Established AD: Activity levels correlate with cognitive decline rate

Therapeutic Strategies

Recombinant ADAMTS13

• Target: Congenital TTP; expanding to neuroprotection
• Delivery: Intravenous or subcutaneous administration
• Dosing: 40 IU/kg weekly in TTP; neuroprotective doses under investigation
• Blood-brain barrier penetration: Limited; may require intranasal or direct CNS delivery

Small Molecule Agonists

Natural compounds that enhance ADAMTS13 activity:

• Curcumin: Shown to increase ADAMTS13 expression in endothelial cells
• Resveratrol: Modulates VWF and ADAMTS13 balance
• Omega-3 fatty acids: Reduce VWF while preserving ADAMTS13

Gene Therapy Approaches

• AAV vectors: Engineered to express ADAMTS13
• Target cells: Hepatocytes for systemic expression
• Challenges: Achieving therapeutic levels in CNS

Clinical Trial Considerations

Patient Selection

• Elevated VWF:ADAMTS13 ratio
• Confirmed AD diagnosis (NIA-AA criteria)
• Stable anti-amyloid therapy if applicable
• No significant coagulopathy

Outcome Measures

• Cognitive batteries (ADAS-Cog, MoCA)
• Cerebral blood flow (ASL-MRI)
• Biomarker normalization (VWF, Aβ)
• Safety: bleeding risk, thrombotic events

Genetic Factors

ADAMTS13 Polymorphisms

| SNP | Function | Population Frequency | Disease Association |
|-----|----------|----------------------|---------------------|
| Q449E | Reduced activity | ~5% Caucasian | TTP modifier |
| P618A | Mild reduction | ~3% | Stroke risk |
| R7W | Altered secretion | Rare | TTP risk |

Gene-Environment Interactions

• Cardiovascular risk factors: Diabetes, hypertension modify ADAMTS13 function
• Smoking: Reduces ADAMTS13 activity
• Age: Natural decline in ADAMTS13 activity with age
• Inflammation: Pro-inflammatory states suppress ADAMTS13 expression

Interaction with Other AD Therapeutic Targets

Amyloid-Targeting Therapies

ADAMTS13 may complement anti-amyloid strategies:

Tau-Targeting Therapies

VWF dysfunction may accelerate tau pathology:

• Ischemia from microthrombi promotes tau phosphorylation
• Reduced cerebral blood flow affects tau clearance
• ADAMTS13 therapy may indirectly reduce tau pathology

Neuroinflammation

ADAMTS13 deficiency contributes to neuroinflammation:

• Microvascular inflammation spreads to parenchyma
• Cytokine release from activated endothelium
• Enhanced microglia activation
• Astrocyte reactivity

Animal Models

ADAMTS13 Knockout Mice

• phenotype: Elevated VWF multimers, reduced cerebral blood flow
• AD model cross: Accelerated Aβ deposition, worsened cognition
• Recovery: ADAMTS13 replacement improves outcomes

Transgenic AD Models

• 5xFAD mice: Reduced ADAMTS13 with disease progression
• APP/PS1 mice: VWF elevation precedes plaque deposition
• Therapeutic response: ADAMTS13 administration improves cerebral blood flow

Summary

ADAMTS13 represents a critical link between vascular function and neurodegeneration in Alzheimer's disease. Its role in cleaving von Willebrand factor multimers directly impacts cerebral microvascular health, blood-brain barrier integrity, and the formation of toxic VWF-Aβ complexes. Therapeutic strategies targeting ADAMTS13—through recombinant enzyme replacement, small molecule agonists, or gene therapy—offer promising approaches to address the vascular components of AD pathogenesis. The growing understanding of ADAMTS13's neuroprotective functions positions it as a valuable biomarker and therapeutic target for neurodegenerative disease intervention.

Mechanism Map

See Also

• [von Willebrand Factor](/proteins/vwf)
• [Blood-Brain Barrier](/mechanisms/blood-brain-barrier)
• [Thrombotic Thrombocytopenic Purpura](https://en.wikipedia.org/wiki/Thrombotic_thrombocytopenic_purpura)
• [Alzheimer's Disease](/diseases/alzheimers-disease)
• [Stroke](/diseases/stroke)

External Links

• [NCBI Gene: ADAMTS13](https://www.ncbi.nlm.nih.gov/gene/11067)
• [UniProt: ADAMTS13](https://www.uniprot.org/uniprot/Q76LX8)
• [OMIM: ADAMTS13](https://www.omim.org/entry/607840)

References